What's Happening?
The Drugs for Neglected Diseases initiative (DNDi), a non-profit organization, has partnered with the Serum Institute of India (SII) to advance a monoclonal antibody-based candidate for dengue into a phase 3 clinical trial. This candidate, previously
known as VIS513, was initially developed by Visterra, a subsidiary of Otsuka. The upcoming trial, set to begin in the first quarter of next year, will involve 1,000 participants across Malaysia, Thailand, and Brazil, regions where dengue is prevalent. Dengue, a viral infection transmitted by Aedes mosquitoes, currently lacks a specific treatment, with existing management focusing on hydration and symptom control. The antibody aims to neutralize all four serotypes of the virus, potentially reducing the severity and duration of the infection. SII has optimized the antibody's formulation and conducted earlier phase trials, showing promising safety and efficacy results. The trial is supported by funding from the EU and France's development agency.
Why It's Important?
This development is significant as dengue affects approximately 390 million people annually, with 20,000 deaths reported. The disease is endemic in over 125 countries, including U.S. territories like Puerto Rico and the U.S. Virgin Islands. The introduction of a therapeutic option could drastically change the management of dengue, offering a post-infection treatment that could alleviate the burden on healthcare systems in affected regions. The collaboration between DNDi and SII highlights the importance of global partnerships in addressing neglected diseases, potentially leading to more accessible and affordable treatments worldwide. The success of this trial could pave the way for similar initiatives targeting other neglected tropical diseases.
What's Next?
Following the phase 3 trial, if successful, the antibody could proceed to regulatory approval and commercialization, providing a much-needed therapeutic option for dengue. The trial's outcomes will be closely monitored by global health organizations and could influence future funding and research priorities in the field of infectious diseases. Additionally, the results may encourage further investment in monoclonal antibody research for other viral infections, expanding the scope of therapeutic options available for neglected diseases.
